Capmatinib is named as an intervention in 3 current clinical trials in our China, USA and UK registers. None are recruiting at the moment. The most common phase is Phase 2. The sponsor with the most trials is Janssen Research & Development, LLC (1). The most-studied condition is Carcinoma, Non-Small-Cell Lung.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
NCT06054191 · ClinicalTrials.gov ↗ · NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
|
Phase 2 | Not yet open | Sun Yat-sen University | China |
|
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
NCT03040973 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Which Are cMET-dependent
|
Phase 2 | Active, closed | Novartis Pharmaceuticals | USA, China |
|
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung
|
Phase 1/2 | Active, closed | Janssen Research & Development, LLC | UK, USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 1 |
| Novartis Pharmaceuticals | 1 |
| Sun Yat-sen University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 0 |
| Clinical trials in USA | 2 | 0 |
| Clinical trials in UK | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, USA and UK registers name Capmatinib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Janssen Research & Development, LLC (1), Novartis Pharmaceuticals (1) and Sun Yat-sen University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Capmatinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Capmatinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Capmatinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.